{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:39:12Z","timestamp":1792370352473,"version":"4.4.0"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    GO is the most frequent extrathyroidal manifestation of Graves\u2019 disease, although it may rarely occur in euthyroid\/hypothyroid patients with chronic autoimmune thyroiditis. It is a relatively infrequent disorder, and men tend to have more severe ocular involvement at an older age. The prevalence of GO is lower than in the past among patients with recent onset Graves\u2019 hyperthyroidism, and moderate-to-severe forms requiring aggressive treatments are no more than 5\u20136% of all cases of GO. After an initial inflammatory (active) phase and a phase of stabilization (plateau phase), GO tends to improve and eventually inactivates (inactive or burnt-out phase). Minimal-to-mild GO often remits spontaneously, but complete\n                    <jats:italic>restitutio ad integrum<\/jats:italic>\n                    almost never occurs when GO is more than mild. Several risk factors contribute to its development on a yet undefined genetic background. Cigarette smoking is the most important of them. Early diagnosis, control and removal of modifiable risk factors, early treatment of mild forms of GO may effectively limit the risk of progression to more severe forms, which have a profound and dramatic impact on the quality of life of affected individuals, and remain a therapeutic challenge, often requiring long-lasting and multiple medical and surgical therapies.\n                  <\/jats:p>","DOI":"10.3389\/fendo.2020.615993","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T01:31:28Z","timestamp":1606699888000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":336,"title":["Epidemiology, Natural History, Risk Factors, and Prevention of Graves\u2019 Orbitopathy"],"prefix":"10.3389","volume":"11","author":[{"given":"Luigi","family":"Bartalena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Piantanida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Tanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMcp0806317","article-title":"Graves\u2019 ophthalmopathy","volume":"360","author":"Bartalena","year":"2009","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0305-4","article-title":"New insights into the pathogenesis and nonsurgical management of Graves\u2019 orbitopathy","volume":"16","author":"Taylor","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01380-9","article-title":"Thyrotropin receptor antibodies and Graves\u2019 orbitopathy","author":"Diana","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01353-y","article-title":"Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves\u2019 orbitopathy","author":"Nicol\u00ec","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01341-2","article-title":"Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves\u2019 disease: results of a pilot study","volume":"43","author":"Lanzolla","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"B9","first-page":"477","article-title":"The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota","volume":"92","author":"Bartley","year":"1994","journal-title":"Trans Am Ophthalmol Soc"},{"key":"B10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1530\/EJE-11-0548","article-title":"Incidence of hyperthyroidism in Sweden","volume":"165","author":"Abraham-Nordling","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1275","article-title":"Incidence and clinical presentation of moderate to severe Graves\u2019 orbitopathy in a Danish population before and after iodine fortification of salt","volume":"97","author":"Laurberg","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13023-017-0625-1","article-title":"Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 Orbitopathy (EUGOGO) position statement","volume":"12","author":"Perros","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves\u2019 orbitopathy in a large series of patients with newly diagnosed Graves\u2019 hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-306733","article-title":"PREGO (presentation of Graves\u2019 orbitopathy) study: changes in referral patterns to European Group on Graves\u2019 Orbitopathy (EUGOGO) centres over the period from 2000 to 2012","volume":"99","author":"Perros","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3325\/cmj.2011.52.615","article-title":"Ten-year follow-up of thyroid epidemiology in Slovenia after increase in salt iodization","volume":"52","author":"Zaletel","year":"2011","journal-title":"Croat Med J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2011.10.05","article-title":"Epidemiology of Graves\u2019 orbitopathy (GO) and relationship with thyroid disease","volume":"26","author":"Lazarus","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.53.1518","article-title":"Graves\u2019 ophthalmopathy: epidemiology and natural history","volume":"53","author":"Hiromatsu","year":"2014","journal-title":"Intern Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1998.8.423","article-title":"Natural history of thyroid associated ophthalmopathy","volume":"8","author":"Perros","year":"1998","journal-title":"Thyroid"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14296","article-title":"Prevalence of thyroid eye disease in Graves\u2019 disease: a meta-analysis and systematic review","author":"Chin","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3275\/8937","article-title":"Prevalence and natural history of Graves\u2019 orbitopathy in the XXI century","volume":"36","author":"Piantanida","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0b013e3181ce5702","article-title":"Proptosis in dysthyroid ophthalmopathy: a case series of 10,931 Japanese cases","volume":"87","author":"Kozaki","year":"2010","journal-title":"Optom Vis Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1993.tb00516.x","article-title":"Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic","volume":"38","author":"Perros","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01991","article-title":"Childhood Graves\u2019 ophthalmopathy: results of a European questionnaire study","volume":"53","author":"Krassas","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1159\/000475968","article-title":"Childhood Graves\u2019 orbitopathy","volume-title":"Graves\u2019 orbitopathy. A multisciplinary approach \u2013 questions and anwers","author":"Bartalena","year":"2017"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.1200473","article-title":"Studies on the occurrence of ophthalmopathy in Graves\u2019 disease","volume":"120","author":"Marcocci","year":"1989","journal-title":"Acta Endocrinol (Copenh)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01258-w","article-title":"Asymmetry indicates more severe and active disease in Graves\u2019 orbitopathy: results from a prospective cross-sectional multicentre study","volume":"43","author":"Perros","year":"2020","journal-title":"J\u00a0Endocrinol Invest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1402","article-title":"Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype","volume":"91","author":"Manji","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1992.tb01445.x","article-title":"Graves\u2019 ophthalmopathy in relation to cigarette smoking and ethnic origin","volume":"36","author":"Tellez","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4294","article-title":"Risk factors for Graves\u2019 orbitopathy; the Australian Thyroid-Associated Orbitopathy (ATOR) study","volume":"101","author":"Khong","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/iop.0000000000000350","article-title":"Predicting the development of orbitopathy in Graves thyroidopathy patients: the potential role of TSI testing","volume":"31","author":"Takakura","year":"2015","journal-title":"Ophthalm Plast Reconstr Surg"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.5103","article-title":"Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease","volume":"133","author":"Stein","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.148049","article-title":"Multi-center study on the characteristics and treatment strategies of patients with Graves\u2019 orbitopathy: the first European Group on Graves\u2019 Orbitopathy experience","volume":"148","author":"Prummel","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/01.iop.0000124675.80763.5","article-title":"Prevalence of asymmetric exophthalmos in Graves orbitopathy","volume":"20","author":"Soroudi","year":"2004","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2008.01.013","article-title":"Long-term multidisciplinary follow-up of unilateral thyroid-associatedorbitopathy","volume":"19","author":"Daumerie","year":"2008","journal-title":"Eur J Intern Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.137265","article-title":"Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy","volume":"93","author":"Eckstein","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2415-13-21","article-title":"Unilateral proptosis in thyroid disease with subsequent contralateral involvement: retrospective follow-up study","volume":"13","author":"Strianese","year":"2013","journal-title":"BMC Ophthalmol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01141-3","article-title":"Orbital diseases mimicking Graves\u2019 orbitopathy: a long-standing challenge in differential diagnosis","volume":"43","author":"Marin\u00f2","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01094-7","article-title":"The clinical phenotype of Graves\u2019 disease occurring as an isolated condition or in association with other autoimmune diseases","volume":"43","author":"Rotondi","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2000.10.1093","article-title":"Graves\u2019 ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels","volume":"10","author":"Khoo","year":"2000","journal-title":"Thyroid"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12129","article-title":"A novel bioassay for anti-thyrotrophin autoantibodies detects both thyroid-blocking and stimulating activities","volume":"173","author":"Li","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0031","article-title":"Prevalence, phenotype, and psychological well-being in euthyroid\/hypothyroid thyroid-associated orbitopathy","volume":"25","author":"Ponto","year":"2015","journal-title":"Thyroid"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.00959.x","article-title":"Association of thyrotrophin receptor antibodies with the clinical features of Graves\u2019 ophthalmopathy","volume":"52","author":"Gerding","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1210\/jc.2016-1220","article-title":"Thyroid stimulating antibodies are highly prevalent in Hashimoto\u2019s thyroiditis and associated orbitopathy","volume":"101","author":"Kahaly","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-014-0171-9","article-title":"Graves\u2019-like orbitopathy: do not forget IgG4-related disease","volume":"37","author":"Bartalena","year":"2014","journal-title":"J Endocrinol Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1089\/105072502761016476","article-title":"Epidemiology and prevention of Graves\u2019 ophthalmopathy","volume":"12","author":"Wiersinga","year":"2002","journal-title":"Thyroid"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1992.2.171","article-title":"Relationship between Graves\u2019 ophthalmopathy and type of treatment of Graves\u2019 hyperthyroidism","volume":"2","author":"Marcocci","year":"1992","journal-title":"Thyroid"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.150.5.1098","article-title":"Effect of abnormal thyroid function on the severity of Graves\u2019 ophthalmopathy","volume":"150","author":"Prummel","year":"1990","journal-title":"Arch Intern Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-014-0171-9","article-title":"Relation between therapy for hyperthyroidism and the course of Graves\u2019 ophthalmopathy","volume":"338","author":"Bartalena","year":"1998","journal-title":"N Engl J Med"},{"key":"B50","article-title":"Development and course of exophthalmos and ophthalmoplegia in Graves\u2019 disease with special reference to the effect of thyroidectomy","volume":"5","author":"Rundle","year":"1945","journal-title":"Clin Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.21.2.0393","article-title":"Management of Graves\u2019 ophthalmopathy: reality and perspectives","volume":"21","author":"Bartalena","year":"2000","journal-title":"Endocr Rev"},{"key":"B52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1046\/j.1442-9071.2004.00756.x","article-title":"Late reactivation of thyroid orbitopathy","volume":"32","author":"Selva","year":"2004","journal-title":"Clin Exp Ophthalmol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-1140","article-title":"Some studies on the natural history of Graves\u2019 orbitopathy: increase in orbital fat is a rather late phenomenon","volume":"173","author":"Potgieser","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association \/European Group on Graves\u2019 Orbitopathy guidelines for the management of Graves\u2019 orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"key":"B55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2265.1995.tb02597.x","article-title":"Natural history of thyroid associated ophthalmopathy","volume":"42","author":"Perros","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B56","article-title":"Graves\u2019 ophthalmopathy: natural history and treatment outcomes","volume":"131","author":"Noth","year":"2001","journal-title":"Swiss Med Wkly"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2013.0240","article-title":"Spontaneous improvement of untreated mild Graves\u2019 ophthalmopathy: Rundle\u2019s curve revisited","volume":"24","author":"Menconi","year":"2014","journal-title":"Thyroid"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-1136-x","article-title":"Natural history of Graves\u2019 orbitopathy after treatment","volume":"57","author":"Menconi","year":"2017","journal-title":"Endocrine"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04318.x","article-title":"Twin studies as a model for exploring the aetiology of autoimmune thyroid disease","volume":"76","author":"Brix","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012513-104713","article-title":"Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics","volume":"9","author":"Tomer","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-014-0214-2","article-title":"Role of genetic and non-genetic factors in the etiology of Graves\u2019 disease","volume":"38","author":"Marin\u00f2","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0007","article-title":"Genetic profiling in Graves\u2019 disease: further evidence for lack of a distinct genetic contribution to Graves\u2019 orbitopathy","volume":"22","author":"Yin","year":"2012","journal-title":"Thyroid"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102653","article-title":"Association between polymorphisms in the TSHR gene and Graves\u2019 orbitopathy","volume":"9","author":"Jurecka-Lubieniecka","year":"2014","journal-title":"PLoS One"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2011.09.004","article-title":"Prevention of Graves\u2019 orbitopathy","volume":"26","author":"Bartalena","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12222","article-title":"Smoking and thyroid","volume":"79","author":"Wiersinga","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.3592","article-title":"Cigarette smoking: number one enemy for Graves\u2019 ophthalmopathy","volume":"126","author":"Bartalena","year":"2016","journal-title":"Pol Arch Med Wewn"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/BF03350047","article-title":"More on smoking habits and Graves\u2019 ophthalmopathy","volume":"12","author":"Bartalena","year":"1989","journal-title":"J Endocrinol Invest"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1001\/jama.269.4.479","article-title":"Smoking and risk of Graves\u2019 disease","volume":"269","author":"Prummel","year":"1993","journal-title":"JAMA"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1996.8220832.x","article-title":"Smoking and endocrine ophthalmopathy: impact of smoking severity and current versus lifetime tobacco consumption","volume":"45","author":"Pfeilschifter","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-8-199810150-00010","article-title":"Cigarette smoking and treatment outcomes in Graves\u2019 ophthalmopathy","volume":"129","author":"Bartalena","year":"1998","journal-title":"Ann Intern Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.6.773","article-title":"Impact of smoking on the response to treatment of thyroid associated ophthalmopathy","volume":"73","author":"Eckstein","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.6.773","article-title":"Thyroid-associated ohthalmopathy after treatment for Graves\u2019 hyperthyroidism with antithyroid drugs or iodine-131","volume":"94","author":"Traisk","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0507","article-title":"A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves\u2019 ophthalmopathy","volume":"90","author":"Perros","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199206253262603","article-title":"Occurrence of ophthalmopathy after treatment for Graves\u2019 hyperthyroidism","volume":"326","author":"Tallstedt","year":"1992","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/biof.5520190308","article-title":"Oxidative stress and Graves\u2019 ophthalmopathy: in vitro studies and therapeutic implications","volume":"19","author":"Bartalena","year":"2003","journal-title":"Biofactors"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2470","article-title":"A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves\u2019 orbitopathy","volume":"95","author":"Lytton","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0430","article-title":"High serum cholesterol is a novel risk factor for Graves\u2019 orbitopathy: results of a cross-sectional study","volume":"28","author":"Sabini","year":"2018","journal-title":"Thyroid"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-018-0915-z","article-title":"Relationship between serum cholesterol and Graves\u2019 orbitopathy (GO): a confirmatory study","volume":"41","author":"Lanzolla","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1159\/000490384","article-title":"European Thyroid Association Guideline for the management of Graves? Hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911163212001","article-title":"Use of corticosteroids to prevent progression of Graves\u2019 ophthalmopathy after radioiodine treatment for hyperthyroidism","volume":"321","author":"Bartalena","year":"1989","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0150","article-title":"Prevention of orbitopathy by oral or intravenous steroid prophylaxis in short duration Graves\u2019 disease undergoing radioiodine ablation: a prospective randomized control trial study","volume":"29","author":"Vannucchi","year":"2019","journal-title":"Thyroid"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-213","article-title":"Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves\u2019 orbitopathy: a retrospective cohort study","volume":"95","author":"Lai","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01126-2","article-title":"Oral steroid prophylaxis for Graves\u2019 orbitopathy after radioactive iodine treatment for Graves\u2019 disease is not only effective, but also safe","volume":"43","author":"Rosetti","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1012985","article-title":"Selenium and the course of mild Graves\u2019 ophthalmopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1210\/jc.-2005-2813","article-title":"Thyrotropin receptor autoantibodies are independent risk factors for Graves\u2019 ophthalmopathy and help to predict severity and outcome of the disease","volume":"91","author":"Eckstein","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1999.9.1175","article-title":"The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves\u2019 disease identifies a group at markedly increased risk of ophthalmopathy","volume":"9","author":"Khoo","year":"1999","journal-title":"Thyroid"},{"key":"B87","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1365-2265.2004.02033.x","article-title":"Thyroid autoantibody profile in ophthalmic dominant and thyroid dominant Graves\u2019 disease differ and suggest ophthalmopathy is a multiantigenic disease","volume":"60","author":"Goh","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B88","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/EJE-07-0450","article-title":"TSH-receptor autoimmunity in Graves\u2019 disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study","volume":"158","author":"Laurberg","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0039","article-title":"Predictive score for the development or progression of Graves\u2019 orbitopathy in patients with newly diagnosed Graves\u2019 hyperthyroidism","volume":"178","author":"Wiersinga","year":"2018","journal-title":"Eur J Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2020.615993\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T01:31:33Z","timestamp":1606699893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2020.615993\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":89,"alternative-id":["10.3389\/fendo.2020.615993"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.615993","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]},"article-number":"615993"}}